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Background: In Saccharomyces cerevisiae, the immunosuppressant rapamycin engenders a profound modification
in the transcriptional profile leading to growth arrest. Mutants devoid of Rrd1, a protein possessing in vitro peptidyl
prolyl cis/trans isomerase activity, display striking resistance to the drug, although how Rrd1 activity is linked to the
biological responses has not been elucidated.
Results: We now provide evidence that Rrd1 is associated with the chromatin and it interacts with RNA
polymerase II. Circular dichroism revealed that Rrd1 mediates structural changes onto the C-terminal domain (CTD)
of the large subunit of RNA polymerase II (Rpb1) in response to rapamycin, although this appears to be
independent of the overall phosphorylation status of the CTD. In vitro experiments, showed that recombinant Rrd1
directly isomerizes purified GST-CTD and that it releases RNA polymerase II from the chromatin. Consistent with
this, we demonstrated that Rrd1 is required to alter RNA polymerase II occupancy on rapamycin responsive genes.
Conclusion: We propose as a mechanism, that upon rapamycin exposure Rrd1 isomerizes Rpb1 to promote its
dissociation from the chromatin in order to modulate transcription.
Background
Rapamycin is an immunosuppressant that was recently
approved for treating kidney carcinomas [1]. It is known
to inhibit the Tor1 (Target of Rapamycin) kinase signal-
ling pathway leading to growth inhibition [2]. In S. cere-
visiae, several factors have been identified through
genome-wide screens that when deleted cause resistance
to rapamycin [3]. One of these proteins is Rrd1 (Rapa-
mycin Resistance Deletion 1) that was first reported to
play a role in protecting cells against oxidative DNA
damage caused by the carcinogen 4-nitroquinoline-1-
o x i d e( 4 - N Q O )a n db yU V A[ 4 ] .M u t a n t sd e f i c i e n ti n
Rrd1 are also unable to undergo rapamycin-induced
growth arrest and therefore exhibit marked resistance to
the drug [5]. Rrd1 is conserved in eukaryotes and shares
35% identity with the human phosphotyrosyl phospha-
tase activator, hPTPA, which was initially isolated as a
protein that stimulated the weak phosphotyrosyl phos-
phatase activity of the type 2A Ser/Thr phosphatase
PP2A [6,7]. We and others reported that Rrd1 can
physically interact with the Ser/Thr phosphatase Sit4, a
PP2A like phosphatase [8-10]. In S. cerevisiae, rapamy-
cin binds to the peptidyl-prolyl cis/trans isomerase Fpr1
and this drug-protein complex inactivates the Tor1
kinase causing a profound modification in the transcrip-
tional profile, and culminating in G1 growth arrest
[11-13]. Inhibition of Tor1 leads to the activation of
Sit4, by virtue of its dissociation from the inhibitor com-
plex Tap42-Sit4, which in turn dephosphorylates several
targets including the nutrient-responsive transcriptional
activator Gln3 that translocates to the nucleus to acti-
vate GLN1 and MEP2 expression [13-15]. However,
these Sit4-dependent processes do not require the func-
tion of Rrd1, suggesting that the latter protein might
execute a function downstream in the Tor1 signalling
pathway [12,16-18].
Recent data indicate that Rrd1 exerts an effect at the
transcriptional level [12,16-18]. Genes known to be upre-
gulated (e.g., the diauxic shift genes CPA2 and PYC1)
a n dd o w n - r e g u l a t e d( e . g . ,t h er i b o s o m a lp r o t e i ng e n e s
including RPS26A, RPL30,a n dRPL9) following rapamy-
cin exposure showed an altered transcription pattern in
rrd1Δ mutants [12,16-18]. To date, the exact function
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not been investigated. Rrd1 and its mammalian counter-
part PTPA have been shown to possess an in vitro peptidyl
prolyl cis/trans isomerase (PPIase) activity on model sub-
strates [19]. PPIases are ubiquitous proteins that catalyti-
cally facilitate the cis/trans isomerization of peptide bonds
N-terminal to proline residues within polypeptide chains
[20,21]. Both Rrd1 and PTPA can independently change
the structure of short peptides including the synthetic sub-
strate (
186LQEPHEGPMCDL
198) representing a conserved
sequence amongst PP2A phosphatases [19]. As such, it has
been suggested that Rrd1/PTPA could activate PP2As via
this PPIase activity [19]. So far, neither the in vivo target
nor the biological function of the PPIase activity of Rrd1
has been elucidated, although this is not the case for other
PPIases. For example, the PPIases Ess1 and Pin1 from
S. cerevisiae and mammalian cells, respectively, possess the
ability to associate with the C-terminal domain (CTD) of
Rpb1 [22,23]. In yeast, the CTD consists of 26 repeats of
the YS2PTS5PS7 heptad sequence and Ess1 has been
shown to stimulate the dephosphorylation of Ser-5 to effi-
ciently terminate transcription of a subset of genes [24].
In this study, we show that Rrd1 is associated with
RNA pol II and isomerizes the CTD of Rpb1 in vivo
and in vitro. Our data suggest a model whereby this iso-
merization leads to the dissociation of RNA pol II from
the chromatin resulting in transcriptional changes. This
s t u d yp r o v i d e si n s i g h ti n t oap o s s i b l en e wm e c h a n i s m
by which RNA pol II could rapidly respond to transcrip-
tional changes.
Methods
Strains, media and plasmids
The strains used in this study were the parents BY4741
(Mat a, his3-1, leu2-0, met15-0, ura3-0), YDL401
(MATa his3Δ200 leu2Δ1t r p 1u r a 3 - 5 2g a l 2g a l Δ108),
and the isogenic mutants rrd1Δ and gln3Δ. Strains were
endogenously and independently tag at the following
loci APN1, RAD52, RRD1, SWE1 and YAP8 as pre-
viously described [25]. Strains bearing Rpb1-TAP was
provided by Tom Begley (Albany, USA). Strains were
grown in either rich (YPD) or selective (SD) media.
Construction of pGFP-SIT4, pGFP-RAD52, pGFP-
RRD1, GST-APN1 was previously described [8]. pGST-
CTD was constructed by amplifying the murine CTD
from plasmid pGCTD [26] and subcloned into pTW340
(provided by Tom Wilson, Michigan, USA). Construc-
tion of the plasmid pGAL-HIS-RRD1 and purification of
HIS-Rrd1 fusion protein were done as previously
reported for pHIS-BLH1 [27].
Spot test analysis
The assay was done as previously described, except that
plates contained rapamycin [28].
Extraction of chromatin-associated proteins
Extraction of proteins bound to chromatin was done as pre-
viously described, except for the high salt extraction [29].
Co-Immunoprecipitation experiments
Co-immunoprecipitation w a sd o n ea sp r e v i o u s l y
described [8], except using 8WG16 antibody (Covance)
covalently coupled to AminoLink matrix (Pierce) and
total extracts [30] prepared from cells expressing either
MYC- or GFP-tagged form of the indicated proteins or
from the untagged parent or rrd1Δ mutant cells. The
matrix with bound proteins was washed four times with
a buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM
NaCl, and 0.1% NP40. The input (5%) used in the
co-immunoprecipitation experiment as well as half the
volume of the matrix were assessed by Western blot
using either anti-MYC, -GFP (Clontech), or -ubiquitin
(Rockland). The remaining half of the matrix was ana-
lyzed separately by Western blot probed with 8WG16
antibody.
GST and GST-CTD purification
Strains bearing either pGST (this laboratory) or pGST-
CTD plasmid were subcultured in 500 ml selective
media to an OD600 of ~1.0, then treated with the appro-
priate drug for the indicated time. Cells were centri-
fuged, washed once with sterile water, and resuspended
in 1.5 ml of yeast extraction buffer and extracts were
prepared as above. The extracts were centrifuged at
3000 rpm in an Eppendorf centrifuge at 4°C for 3 min.
Lysates were diluted 3-4 folds in PBS and Triton X-100
was added to a final concentration of 0.2%. One and
half ml of glutathione sepharose 4B matrix (Pharmacia)
was equilibrated with 50 ml of PBS in 50 ml Falcon
tube then the lysate (~80 mg) was added and allowed to
bind for one hour at room temperature on a rotating
platform. The matrix was washed 3 times with PBS then
transferred to 10 ml disposable column (BioRad). Excess
of PBS was allowed to flow through, then GST-CTD
was eluted with 10 fractions each of 150 μlo f5 0m M
Tris-HCl pH 9.0, 20 mM reduced glutathione (Sigma).
Peak fractions were pooled to a total volume of 750 μl
and the buffer was exchanged to 500 μl phosphate
buffer using centricon (Millipore). Purity of the samples
was verified by SDS-PAGE followed by silver staining.
Purification of Rpb1-TAP
Proteins were extracted from untreated or rapamycin-
treated (200 ng/ml for 1 h) cells as above and 2 mg
were added to 40 μl of pre-equilibrated calmodulin affi-
nity beads (Stratagene, USA). Purifications and washes
were performed as described for the batch purification
protocol provided by the manufacturer (Stratagene,
USA). Eluates (50 μl) were collected, boiled and loaded
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Page 2 of 10onto SDS-PAGE for Western analysis. After probing
with H5 or H14 antibody (Covance) membranes were
stripped and re-probed with anti-PAP antibody (Sigma,
USA).
Western blot analysis of GST, GST-CTD and Rpb1-TAP
BY4741 parent or rrd1Δ mutant cells expressing the
GST-CTD or carrying the endogenous Rpb1-TAP tag
were subcultured in the appropriate media and treated
with rapamycin (200 ng/ml for 30 min). Whole cell
extracts or where indicated affinity purified proteins
(GST, GST-CTD or Rpb1-TAP using manufacturer’s
protocol (Stratagene, USA))w e r ea n a l y z e db yW e s t e r n
blot with anti-GST (Sigma), H5 (anti-Ser2 phosphory-
lated) and H14 (anti-Ser5 phosphorylated) antibodies
(Covance) or anti-PAP (Sigma).
Interaction between Rrd1-MYC and GST-CTD
Total protein extracts derived from parent cells (100 ml)
expressing GST-CTD or GST-Apn1, untreated or treated
with rapamycin (200 ng/ml for 2 h) were allowed to bind
to 1 ml GST affinity matrix slurry as described for the
purification, except samples were not eluted from the
columns. A second protein extract (1 mg) derived from a
strain expressing Rrd1-MYC or Yap8-MYC was applied
and allowed to bind for 1 h at room temperature on a
rotating platform. The columns were then washed with
20 bed volumes of PBS and an aliquot of the beads
(30 μl) was loaded onto an 8% SDS-PAGE and processed
for Western blot. The presence of GST-CTD on both
columns was detected using polyclonal anti-GST (Sigma)
and the bound Rrd1-MYC was revealed using anti-MYC
monoclonal antibody (SantaCruz).
Circular dichroism spectroscopy
Continuous far-UV circular dichroism spectra (197-
250 nm) of the GST and the GST-CTD fusion protein
(2.0 μg and 4.32 μg, respectively, in 100 μlo f1 0m M
phosphate buffer pH 7.0, 50 mM NaCl) were collected
using a Jasco-810 spectropolarimeter. The measure-
ments were carried out at room temperature using a
1 mm path-length cuvette (Hellma) and a 1 nm band-
width. Three spectra were collected for each sample and
averaged. The spectral contribution of the buffer was
corrected for by subtraction. Relative ellipticity was
converted to mean residue molar ellipticity [Θ] accord-
ing to Fasman [31].
Limited chymotrypsin digestion assay
The purified GST-CTD (~100 ng) derived from parent
cells untreated or treated with rapamycin (200 ng/ml for
2 h) was subjected to digestion with 5 ng chymotrypsin
(Roche) in the presence of 1 mM CaCl2,a n di n c u b a t e d
at 37°C for the indicated time. Digestion was stopped by
the addition of SDS-PAGE loading buffer and boiling of
the samples. Processing of the GST-CTD was analyzed
using 8% SDS-PAGE followed by staining with silver.
In vitro isomerase assay
Purified HIS-Rrd1 (from E. coli using Talon affinity
column according to the manufacturer (GE) protocol)
was added to the purified GST-CTD in sodium
phosphate buffer (10 mM NaPO4 pH 7.0, 50 mM NaCl)
without or with 1 mM MgCl2, and 1 mM ATP in a final
volume of 200 μl. The proteins were incubated for 1 h at
30°C the GST-CTD was recovered by GST-affinity purifi-
cation and then subjected to CD analysis.
In Vitro Rpb1 release assay
Exponentially growing culture (200 ml) of the BY4741
rrd1Δ Apn1-MYC strain was prepared and lysed as
above for the extraction of chromatin associated
proteins. Supernatant was discarded and the pellet was
washed once in 1 ml of isomerization buffer (10 mM
NaPO4 pH 7.0, 50 mM NaCl, 1 mM MgCl2, and 1 mM
ATP). Supernatant was discarded again and pellet was
resuspended in 600 μl of isomerization buffer and
equally divided in three tubes. Increasing amounts of
purified HIS-Rrd1 were added and samples were rocked
f o r1ha t3 0 ° C .S a m p l e sw e r et h e ns p u nd o w na n d
supernatant was kept for subsequent western blot analy-
sis. The remaining pellet was resuspended in benzonase
buffer (50 mM Tris pH 8.0, 1 mM MgCl2)a n d1μlo f
benzonase (Novagen) was added and tubes were
incubated for 30 min at 37°C. Supernatant (SOL) and
chromatin (CHR) fractions were loaded onto SDS-PAGE
gels for Western blot analysis with 4H8 (Cell Signaling)
and anti-MYC antibodies.
ChIP assay
T h eC h I Pa s s a yw a sd o n ea sp r e v i o u s l yd e s c r i b e d[ 3 2 ] .
Primers are available upon request. ACT1 was used as
an endogenous control and relative quantity was calcu-
lated using the ΔΔCT method (Applied Biosystems). IP’s
were normalized to the respective input. Untreated IP
samples were given an arbitrary unit 1 and increase or
decrease folds were calculated. At least three indepen-
dent experiments were done for each gene and Student
T test was used to calculate the p-value.
Results
Rrd1 is associated with the chromatin and
interacts with Rpb1
We previously demonstrated that Rrd1 is required to
modulate the expression of a subset of rapamycin-
regulated genes independently of Sit4 [18]. To corrobo-
rate our earlier findings that Rrd1 acts separately from
the Sit4-Gln3 signaling pathway, we deleted the RRD1
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tant to rapamycin) and examined the resulting gln3Δ
rrd1Δ double mutant for the level of resistance to the
drug [33]. This genetic analysis revealed that the gln3Δ
rrd1Δ double mutant was significantly more resistant to
rapamycin than either of the single mutants (Additional
file 1 Figure S1), suggesting that Rrd1 performs a
distinct role to regulate response to the drug.
To investigate this potentially novel role of Rrd1, we
first checked whether Rrd1 binds to chromatin in light of
its involvement in gene regulation [18]. Chromatin frac-
tions were derived from strains expressing MYC-tagged
R r d 1 ,a sw e l la st h ec o n t r o lp r o t e i n sS w e 1 ,R a d 5 2a n d
Apn1 from the endogenous loci and subjected to
Western blot analysis probed with anti-MYC antibody.
A ss h o w ni nF i g u r e1 A ,as i g nificant amount of Rrd1-
MYC was found in the chromatin fraction (lane 3),
suggesting that Rrd1 is associated with the chromatin
and consistent with an earlier study showing that Rrd1 is
also present in the nucleus [8]. In contrast, the control
protein Swe1-MYC was only found in the soluble fraction
(lane 2), while Rad52-MYC and Apn1-MYC, two DNA
repair proteins known to bind chromatin, were present
in the chromatin fraction (lane 3) [34,35].
Since Rrd1 is bound to the chromatin and is involved
in regulating gene expression, we tested if it is asso-
ciated with RNA pol II by performing co-immunopreci-
pitation analysis. For this experiment, we used total
extracts derived from cells expressing either Rrd1-MYC
or Swe1-MYC and checked for the pull-down with anti-
Rpb1 (8WG16). Rrd1-MYC was co-immunoprecipitated
with Rpb1, but not the control protein Swe1-MYC
(Figure 1B). Since only a small amount of Rrd1-MYC
was co-immunoprecipitated with anti-Rpb1, the associa-
tion between Rrd1 and RNA pol II may be weak or
transient. There was no alteration in the amount of
Rrd1 co-immunoprecipitated by anti-Rpb1 when cells
were treated with rapamycin (200 ng/ml for 30 min)
(Figure 1B).
Anti-Rpb1 also co-immunoprecipitated Rrd1 from par-
ent cells carrying a plasmid expressing GFP-tagged Rrd1
(Figure 1C). In addition, the Sit4 phosphatase known to
physically interact with Rrd1 [8] co-immunoprecipitated
with Rpb1 from parent cells expressing this protein as
GFP fusion (Figure 1C). Two additional GFP fusion pro-
teins, GFP-Imp2 and GFP-Rad52, which do not interact
with Rrd1, were not co-immunoprecipitated with anti-
Rpb1 antibody, although a minute amount of GFP-Rad52
non-specifically interacted with the beads used for immu-
noprecipitation (Figure 1C, and data not shown). Thus,
Rpb1 associates with proteins known to bind Rrd1, sug-
gesting that Rrd1 could exist in a complex with Rpb1.
We note that the reverse co-immunoprecipitation with
Rrd1-MYC did not pull down Rpb1 under the same reac-
tion conditions, raising the possibility that the size of the
RNA pol II complex might impede the pull down
although we cannot exclude other alternatives such as a
weak or indirect interaction via another protein.
Rrd1 associates with the CTD of Rpb1 and alters its
structure in response to rapamycin
Since the C-terminal domain (CTD) of Rpb1 is a
repeated sequence (YSPTSPS) rich in proline residues,
and has previously been shown to bind the isomerases
Ess1 and Pin1 [22,23,36], we reasoned that Rrd1 could
function to isomerize the CTD. As such, we assessed
w h e t h e rt h eC T Di sas u b s t r a t ef o rt h eP P I a s ea c t i v i t yo f
Rrd1 in vivo.T h eC T Dw a se x p r e s s e da saG S Tf u s i o n
protein from a previously described plasmid (see Meth-
ods) and has been shown to undergo post-translational
modifications including Ser-5 and Ser-2 phosphorylation,
isomerization and ubiquitylation [24,26,37,38]. Introduc-
tion of this plasmid into the parent and rrd1Δ strains
directed the expression of the GST-CTD fusion protein
with the expected size (95-kDa) as determined by
Western blot analysis probed with anti-GST antibodies
Figure 1 Rrd1 is associated with the chromatin and interacts
with Rpb1. A) Rrd1 is bound to chromatin. Whole cell extract
(WCE), soluble (SOL) and chromatin (CHR) fractions were derived
(see Methods) from the parent cells expressing either Rrd1-MYC,
Swe1-MYC, Rad52-MYC or Apn1-MYC and the distribution of the
MYC-tagged proteins was examined by Western blots. The data is
representative of two independent analyses. B) Rpb1 pull-down of
Rrd1. The 8WG16 antibodies were used to immunoprecipitate
extracts from untreated (-) and rapamycin-treated (+) (200 ng/ml for
30 min) cells expressing either Rrd1-MYC or Swe1-MYC. The
presence of Rrd1 in the immunoprecipitates was determined by
Western blotting. C) Specificity of Rpb1 pull-down of GFP tagged
proteins. The 8WG16 antibodies were used to immunoprecipitate
extracts from cells expressing either of the following GFP tagged
proteins: Imp2, Rrd1, Rad52 or Sit4. The presence of the GFP-tagged
proteins in the immunoprecipitates was detected by Western
blotting using GFP antibody.
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GST-CTD contained both phosphorylated Ser-5 and Ser-
2 as detected by anti-H14 and anti-H5 antibodies, which
specifically recognize Ser-5 and Ser-2 phosphorylation,
respectively (Figure 2A), consistent with previous studies
that the GST-CTD can be functionally modified in vivo
[26,37-39]. From these analyses, we observed no differ-
ences in the (i) size, (ii) level of expression, and (iii) phos-
phorylation of the GST-CTD whether it was derived
from the parent or the rrd1Δ mutant or from cells that
were pretreated with rapamycin (Figure 2A Additional
file 1 Figure S2).
We next prepared GST-CTD affinity beads from par-
ent cells and determined whether these could pull down
Rrd1. Total extract derived from the parent strain
expressing Rrd1-MYC (Figure 2B, lane 2) was incubated
with the GST-CTD affinity beads. The beads were
recovered, washed and an aliquot examined for reten-
tion of Rrd1-MYC by Western blot analysis. As shown
in Figure 2C and 2D, Rrd1-MYC was pulled down by
the GST-CTD affinity beads. In contrast, the GST-CTD
affinity beads did not pull down the transcriptional acti-
vator Yap8, also tagged with MYC (Figure 2B, C and
2D). As expected, the empty beads did not pull down
Rrd1-MYC from the total extract nor did the control
beads carrying GST-Apn1 (Figure 2C and 2D). These
data support the notion that Rrd1 associates with the
CTD of Rpb1, consistent with the above observation
that Rpb1 co-immunoprecipitated Rrd1.
We next investigated whether Rrd1 could induce con-
formational changes in the GST-CTD fusion protein by
using circular dichroism (CD) spectroscopy, a method
that is very sensitive to changes in the secondary struc-
ture of proteins [31]. We first purified the GST-CTD
from the parent and the rrd1Δ m u t a n t ,a sw e l la sG S T
from the parent to be used as the control. Silver stain
analysis of the purified GST-CTD revealed that there
was no difference in the size of this protein, whether it
was derived from the parent or the rrd1Δ mutant
(Figure 3A, lane 3 vs. 5) or when the cells were treated
with rapamycin (lane 3 vs. 4 or 5 vs. 6). As observed for
total extract, the purified GST-CTD also contained both
Figure 2 Analysis of the GST-CTD and its interaction with Rrd1.
A) Comparison of the expression and phosphorylation status of the
GST-CTD between parent and rrd1Δ mutant cells following
rapamycin exposure. The indicated cells expressing GST-CTD were
treated with (+) and without (-) rapamycin (200 ng/ml for 30 min)
and total protein extracts were probed for Ser-2 phosphorylation
(H5) or Ser-5 phosphorylation (H14). The membranes were stripped
and reprobed with anti-GST antibody. B-D) Retention of Rrd1-MYC
by GST-CTD affinity beads. B) The input (5% of the total amount of
protein extracts added to the beads) of parent cells expressing
Yap8-MYC and Rrd1-MYC from the endogenous locus. Western blot
analysis was done using anti-MYC antibody. C) and D) Total protein
extracts derived from the parent or parent expressing either Yap8-
MYC or Rrd1-MYC were incubated with the empty beads or beads
containing either GST-CTD or GST-Apn1 (see Methods). The beads
were then washed and an aliquot examined for retention of the
MYC tagged proteins using anti-GST antibodies (C) or anti-GST
antibodies (D). Results shown are representative of two
independent experiments.
Figure 3 rrd1Δ mutants are unable to induce conformational
changes to the GST-CTD in response to rapamycin. A) Silver
stained gel of purified GST and GST-CTD. The indicated strains
carrying either the GST (lanes 1 and 2) or GST-CTD expressing
plasmid (lanes 3-6) were untreated (-) or treated (+) with rapamycin
(RAP) (200 ng/ml for 30 min). B) Far-UV circular dichroism (CD)
spectral analysis of purified GST-CTD. The purified GST-CTD
(0.45 μM) was derived from the parent strain (triangle) or rrd1Δ
mutant (circle) that were untreated (opened symbol) or treated
(closed symbol) with rapamycin. C) Far-UV CD spectral analysis of
purified GST-CTD. The purified GST-CTD (0.45 μM) was derived from
the rrd1Δ mutant carrying the empty vector (circle) or the pRRD1
plasmid (triangle) that were untreated (opened symbol) or treated
(closed symbol) with rapamycin. D) CD analysis of purified GST
(0.76 μM) derived from untreated (opened symbol) and rapamycin
treated (closed symbol) parent cells as above. Results shown are the
averages of two independent experiments. E) Limited proteolysis of
purified GST-CTD derived from parent cells untreated or treated
with rapamycin. The purified GST-CTD was subjected to partial
chymotrypsin digestion and analyzed by silver staining. Results
shown are representative of two independent experiments.
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alteration in response to rapamycin (Additional file 1
Figure S2A). To ensure that the observed phosphoryla-
tion status of the GST-CTD is similar to Rpb1 CTD
phosphorylation, we purified Rpb1 from the TAP tagged
strains and monitored this protein for its phosphoryla-
tion. Like the GST-CTD, Rpb1-TAP showed no differ-
ences in either Ser-5 or Ser-2 phosphorylation following
rapamycin treatment (Additional file 1 Figure S2B).
However, this approach may not distinguish between
subtle phosphorylation differences that may occur
amongst the heptad repeats [40]. Since the GST-CTD is
similarly phosphorylated as the endogenous Rpb1, we
used it as a tool for further analysis.
CD spectra obtained for the purified GST-CTD
derived from either the untreated parent or rrd1Δ
mutant were indistinguishable, and displayed a mini-
mum at 202 nm (Figure 3B). In contrast, GST-CTD
derived from the parent cells treated with rapamycin
exhibited a spectrum with a minimum at 208 nm and
shoulder at ~225 nm (Figure 3B), suggesting that the
GST-CTD underwent a detectable change in its second-
ary structure. Remarkably, rapamycin treatment of the
rrd1Δ mutant failed to induce this conformational
change onto the GST-CTD (Figure 3B). Introduction of
a single copy plasmid expressing functional Rrd1 in the
rrd1Δ mutant restored the change in the spectral
pattern of the GST-CTD (Figure 3C) [4]. Additionally,
purified GST alone derived from untreated or rapamycin
treated parent cells did not exhibit any structural differ-
ences, suggesting that it is the CTD portion of the
fusion protein that is undergoing the rapamycin-induced
changes (Figure 3D). We further confirmed the struc-
tural change of the GST-CTD as observed by CD using
limited proteolysis with chymotrypsin, which can distin-
guish proteins with different secondary structures and
exclusively cleaves peptides int h et r a n s - p r o l i n ec o n f o r -
mation [41]. As shown in Figure 3E, the GST-CTD pur-
i f i e df r o mt h er a p a m y c i n - t r e a t e dp a r e n tc e l l sw a sm o r e
resistant to limited chymotrypsin digestion, as opposed
to the GST-CTD derived from the untreated cells, sug-
gesting that indeed the GST-CTD went through a struc-
tural reorganization in response to rapamycin. On the
basis of these findings, it would appear that the CTD of
Rpb1 changes its structure in vivo following exposure to
rapamycin, and that Rrd1 is essential for this alteration.
Rrd1 alters the GST-CTD structure in response to 4-NQO,
but not MMS
We next checked if isomerization of the CTD is specific
for rapamycin. Since the rrd1Δ mutant was previously
shown to be sensitive to the DNA damaging agent
4-NQO [4], which induces oxidative stress as well as
creating bulky lesions onto the DNA [42], we examined
for isomerization of the GST- CTD in the parent and
the mutant following treatment with this drug. We
observed that the structure of the GST-CTD was altered
in the parent, but not in the rrd1Δ mutant following
4-NQO treatment (Figure 4A). We also tested another
DNA damaging agent, methyl methane sulfonate (MMS)
(Figure 4B), to which the rrd1Δ mutant displays parental
sensitivity [4]. MMS creates apurinic/apyrimidinic sites
in the genome, and for this experiment it was used at a
concentration that kills ~70% of the cells. Under this
condition, the GST-CTD showed no structural altera-
tion following the MMS treatment (Figure 4B). On the
basis of these findings, it would appear that this phe-
nomenon might occur for other stress conditions
besides exposure to rapamycin.
Rrd1 directly alters the structure of the CTD in vitro
We next examined whether purified Rrd1 can induce
structural changes onto the CTD in vitro.T od ot h i s ,
we incubated equimolar amounts of recombinant
HIS-Rrd1 purified from E. coli (Figure 5A) with affinity
purified GST-CTD derived from the rrd1Δ mutant at
30°C for 30 min, and then recovered the GST-CTD for
CD analysis. As shown in Figure 5B, purified HIS-Rrd1
significantly modified the CTD structure under the
Figure 4 4-NQO, but not MMS, induces structural changes onto
the GST-CTD. A and B) CD analysis of the purified GST-CTD
derived from exponentially growing parent (triangle) and rrd1Δ
mutant (circle) that were untreated (opened symbol) or treated
(closed symbol) with either 4-NQO (2 μg/ml 30 min) panel A or
MMS (1% for 60 min) panel B.
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Page 6 of 10standard phosphate buffer reaction conditions. Since the
Rrd1 isomerase activity has been shown to be stimulated
by ATP and Mg
2+ [19], we examined the effect of these
additions to the reaction mixture. Inclusion of ATP and
Mg
2+ in the buffer caused no structural alteration to the
CTD in the absence of Rrd1 (Figure 5B). However, addi-
tion of purified HIS-Rrd1 to the complete ATP/Mg
2+
phosphate buffer introduced a more dramatic change to
the CTD structure, as compared to the mixture lacking
ATP/Mg
2+ (Figure 5B). Moreover, the purified HIS-Rrd1
did not confer any structural changes onto another puri-
fied GST fusion protein, GST-Apn1 (data not shown).
These findings suggest that Rrd1 can directly isomerize
the CTD.
Comparison of RNA pol II occupancy at rapamycin-
responsive genes
Since Rrd1 associates with and isomerizes the CTD, and
that rrd1Δ mutant did not affect the phosphorylation
status of Rpb1, we asked whether it would alter RNA
pol II occupancy on rapamycin responsive genes in vivo.
To do this, we performed chromatin immunoprecipita-
tion (ChIP) analysis of Rpb1 on two known RNA pol
II-responsive genes, RPS26A and CPA2 [32]. Since both
genes are known to be rapidly downregulated and upre-
gulated, respectively, within 30 min, we treated cells for
this time period with rapamycin [11,18]. In parent cells,
the Rpb1-ChIP signal from the RPS26A gene was
reduced by nearly 8-fold upon rapamycin treatment
(Figure 6A). In contrast, Rpb1 remained associated with
RPS26A in the rrd1Δ mutant (Figure 6A). In the case of
the upregulated gene CPA2, we observed an increase in
Rpb1-ChIP signal in the parent upon rapamycin,
whereas in the mutant there was only a modest increase
i nt h es i g n a l( F i g u r e6 B ) .T h eo c c u p a n c yo fR N Ap o lI I
on these genes is consistent with the mRNA expression
levels [11,18]. These data raise the possibility that Rrd1
might displace Rpb1 in order to optimize rapid tran-
scriptional changes caused by rapamycin.
Purified Rrd1 stimulates the release of chromatin-bound
RNA pol II in vitro
To explore the above possibility, we examined if purified
Rrd1 would displace RNA pol II from the chromatin.
Briefly, we isolated chromatin containing RNA pol II
derived from the rrd1Δ mutant, the chromatin was
washed and resuspended in the standard phosphate buf-
fer containing ATP and Mg
2+. To this reaction, increas-
ing amounts of purified Rrd1 was added and following
incubation the levels of chromatin-bound and soluble
Rpb1 were monitored by Western blot. As shown in
Figure 7 increasing concentration of Rrd1 caused a loss
of chromatin-bound Rpb1, while there was a correlating
gain in the soluble fraction. In contrast, Rrd1 concentra-
tion did not affect the level of the control protein Apn1-
MYC. Collectively, our data indicate that Rrd1 possesses
the ability to isomerize the CTD of Rpb1 thereby pro-
moting its displacement from the chromatin.
Discussion
In the present study, we show that Rrd1 is a chromatin
bound protein, which associates with RNA pol II and
presumably through the CTD of Rpb1. We believe that
this association allows isomerization of the CTD in
response to specific stress such as that caused by
Figure 5 Purified recombinant Rrd1 alters the structure of
purified GST-CTD in vitro. A) Silver stained gel of purified
recombinant HIS-Rrd1 from E. coli expression system (see Methods).
Lanes 1-2 and 3-4 are elution samples from two independent
purifications obtained directly from Talon affinity column; lane 5,
molecular weight standard. B) Equimolar amounts (4.5 μM) of
purified GST-CTD derived from the rrd1Δ mutant and the purified
recombinant HIS-Rrd1 (triangle) were incubated at 30°C in
phosphate buffer in the absence (opened symbol) and presence
(closed symbol) of Mg
2+/ATP. The resulting GST-CTD was re-purified
free of the recombinant HIS-Rrd1 and subjected to CD analysis as in
Figure 3. The result is the average of two independent experiments.
Figure 6 Comparison of RNA pol II occupancy at the indicated
target genes in the parent and rrd1Δ mutant strain in
response to rapamycin treatment. Cells were untreated or treated
with 200 ng/ml rapamycin for 30 min and Rpb1 localization was
analyzed by ChIP assay (see Methods). Primer locations are indicated
below the diagram. The respective input normalized IP amounts
were quantified relative to the ACT1 gene using the ΔΔCT method.
Results are shown as the average of three independent
experiments. Error bars represent standard deviation and the
P-values compare untreated vs. treated.
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Page 7 of 10rapamycin and 4-NQO. In addition, we show that in
vitro purified Rrd1 (i) can directly alter the structure of
the CTD and (ii) dissociate Rpb1 from the chromatin.
On the basis of these observations, we propose the fol-
lowing model whereby in response to specific stress
conditions the RNA pol II associated Rrd1 isomerizes
the CTD of Rpb1 such that the polymerase is disso-
ciated from the chromatin. Once the RNA pol II is
released it would be recruited to stress-responsive genes.
There is supporting evidence that elongating RNA pol
II is in excess on ribosomal protein genes, surprisingly
associated with a low transcriptional rate under glucose
grown conditions [43]. However, once these cells are sub-
mitted to a metabolic change, e.g., a switch to galactose
growth conditions, the level of RNA pol II decreased on
these ribosomal genes and the transcriptional rate
increased [43]. This shift also simultaneously caused an
enrichment of RNA pol II onto mitochondrial genes [43].
This suggests a mechanism where excessive RNA pol II
is removed from the ribosomal genes and recruited to
mitochondrial genes to increase expression. Therefore,
metabolic switches would stimulate re-localization of
elongating RNA pol II from one regulon to the other. As
it is known that rapamycin mimics starvation conditions
and represses ribosomal biogenesis, we suspect a similar
mechanism as the glucose-galactose shift is operational
to rapidly change transcription. Besides Rrd1, another
well characterized peptidyl prolyl isomerase Pin1 can
trigger the release of RNA pol II from transcribing genes
in human cells [23]. Under normal conditions, Pin1 inter-
acts with the phosphorylated CTD of RNA pol II and this
association is retained along the length of transcribed
g e n e s[ 2 3 ] .H o w e v e r ,w h e nP i n 1i so v e r e x p r e s s e di t
promotes hyperphosphorylation of the CTD during the
transition from initiation to elongation, thereby causing
RNA pol II to dissociate from active genes and leading to
the inhibition of transcription [23,44]. The dissociated
RNA pol II accumulates in enlarged speckle-associated
structures enriched for transcription and RNA processing
factors [23,45].
Because Rrd1 intersects with the biological functions
of Pin1, it is possible that Rrd1 could modulate the
phosphorylation status of the CTD. Recent studies
showed that the yeast homologue of Pin1, Ess1, binds
and catalyzes the cis/trans isomerization of the CTD
such that Ser-5 phosphorylation can be dephosphory-
lated by the Ssu72 phosphatase [24]. Moreover, a variant
of Ess1 (Cys120Arg) caused accumulation of Ser-5 phos-
phorylation, and not Ser-2 phosphorylation, both of
which were monitored using the same set of antibodies
(anti-H5, -H14 and -8WG16) as in this study [24]. We
found no alteration in the glo b a lS e r - 2a n dS e r - 5p h o s -
phorylation status upon rapamycin treatment, as well as
between the parent and the rrd1Δ mutant using the
same set of antibodies (Figure 2A and Additional file 1
Figure S2). As such, it would seem that Rrd1 uses a
novel mechanism independent of phosphorylation to
isomerize the CTD, although we cannot exclude the
possibility that there are unique Ser-2 and Ser-5 phos-
phorylation differences which can be masked by neigh-
boring phosphorylations, for example, where one heptad
is phosphorylated, but not the adjacent [40]. However,
since RNA pol II exists in different phosphorylation
forms throughout the transcription cycle, it seems logi-
cal to have a mechanism that triggers RNA pol II
release independent of its phosphorylation status.
In yeast, the CTD consists of 26 repeats of the heptad
sequence YSPTSPS. It exists largely in a disordered
structure, but adopts a static conformation upon inter-
action with target proteins such as the mediator com-
plex that regulates transcription initiation and enzymes
that modify the 5’ and 3’ends of mRNA [46,47]. Binding
of these proteins to the CTD is modulated by serine
phosphorylation and proline isomerization [40]. Thus, a
given heptad repeat could give rise to many different
conformations with the various combinations of phos-
phorylated Ser-2, -5 and -7, as well as the cis/trans iso-
merization of the two prolines, Pro-3 and Pro-6, to
generate a broad range of binding sites to allow precise
association with several factors [46-48]. At least three
CTD interacting proteins (Pcf1, Pin1, and Ctg-1 from
C. albicans) have been shown to bind exclusively the
all-trans conformation, providing support for the
hypothesis that proline isomerization of the CTD plays
a critical regulatory role [48]. This strongly suggests that
multiple conformations of the CTD exist in vivo.C o n -
sistent with this notion, we observed by CD analysis two
conformations of the CTD that remained stable
throughout its purification (Lisa Miller, Brookhaven
National Laboratories, personal communications) from
untreated and rapamycin-treated cells (Figure 3). These
different conformations could be the result of proline
Figure 7 Purified recombinant Rrd1 dissociates Rpb1 from the
chromatin in vitro. Increasing amounts of purified HIS-Rrd1 were
added to the chromatin fraction isolated from rrd1Δ mutant strain
expressing Apn1-MYC and incubated at 30°C for 1 h in phosphate
buffer. Chromatin was recovered from the buffer and both fractions
were analyzed by Western blotting probed with 4H8 (against Rpb1)
and anti-MYC antibodies. Apn1-MYC was used as loading control.
Result shown is representative of at least three experiments.
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either the cis or trans conformation when the protein is
in a folded form [49]. Only peptidyl prolyl isomerases
such as Pin1/Ess1 are known to trigger a switch between
the cis and trans conformations of the CTD [50], and
that in the absence of these enzymes the conformational
switch is slow [51]. Because Rrd1 possesses peptidyl pro-
lyl isomerase activity and it associates with RNA pol II,
it seems likely that this function is responsible for indu-
cing structural changes to the CTD upon rapamycin
exposure. In support of this, Rrd1 directly alters the
CTD structure in vitro (Figure 5), and we therefore pre-
dict that Rrd1 might act in a similar manner onto the
CTD in vivo.
In addition to rapamycin, we also observed that the
DNA damaging agent 4-NQO, but not MMS, triggered
alteration of the CTD structure (Figure 4). We exam-
ined the effect of 4-NQO, as we had previously shown
that rrd1Δ mutants were sensitive to this agent and not
to MMS [4]. The distinct difference between 4-NQO
and MMS is that the former agent potently induces the
production of reactive oxygen species such as superox-
ide anions [42]. Both starvation and oxidative stress are
known to mediate similar transcriptional programs, also
termed as the environmental stress response, for exam-
ple, where ribosome biogenesis is turned off [51,52].
This would explain why the rrd1Δ mutants are sensitive
to 4-NQO, but resistant to rapamycin; (i) genes required
for counteracting the 4-NQO-induced oxidative stress
are not turned on efficiently and as a result the cells
accumulate genotoxic lesions, and (ii) under rapamycin
condition nutrients are still available and the failure to
alter gene expression allows rrd1Δ mutants to grow.
Conclusions
Taken together, our data suggest that Rrd1 participates
in a novel mechanism that allows redistribution of RNA
pol II for transcriptional regulation of genes involved in
specific stress conditions. These results provide the first
direct evidence that Rrd1 acts in vivo as an isomerase
and establish a physiological function for this activity.
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